WeGovy’s weight loss drug class, sold as Wegoy, has become awesome new treatments for obesity. It is a key factor in efficiency that people should take them indefinitely, but in practice, many do not. A new Jama Network open An exam was found Most people have stopped taking these drugs in two yearsStoping in treatment often reverses weight loss and health profits. Many clinicians who use and prescribe these drugs ask how durable and what they are going to leave about the long-term health.
Many growing evidence shows People can be overweight and wholesomeBut the relationship between health and weight is complex. It can be a higher risk of serious illness. New medications, technically glucogic peptide (GLP-1) agonists, used to promote significant weight loss, is a number of cardiometabolic improvements and type 2 diabetes. (The drug is a semaglutide shape sold as ozempic.) But a person who was taking one of these medications is taken Eliminated her hunger They often go back, which causes weight return. Other health benefits of drug health, such as high blood pressure, tends to return to the treatment after stopping. Some evidence suggests that certain cardiomolic benefits can last, but only humbly.
The study later had more than 120,000 people, and without type 2 diabetes, those who were taking GLP-1 medications. All were considered overweight or 61 percent had type 2 diabetes. The researchers found half of the participants left the treatment in his one year, and almost three quarters were made for the second year. Going-off was even greater among those with type 2 diabetes: 85% after two years. The study did not investigate the impact of using GLP-1 medications, but previous human studies have found that weight recovery is almost essential.
To help Science Journalism
If you enjoy this article, consider entering award-winning journalism Subscribe. By purchasing subscription, you are helping to ensure the future of stories about the discoveries and ideas that are conformed to today.
These drugs mimiculate intestinal hormones that slow down digestion, bending the body of the body full, in the end. “Food noise returns when medication stops,” says Janice Jin Hwang, the leader who distributes endocrinology and metabolism at medicine school at medicine and metallism.
Maintaining weight is not as easy as it is to ignore food; Some research suggest that the human body does not lose weight and actively works against it. It is an explanation about this what researchers call Set the theory of the pointThis suggests that each person tries to keep their body naturally. “When you start losing weight, your body really fits to try to hold on weight,” Hwang explained. A Cascade of biological answers He throws the body as he tries to “defend” his weight: the guts begin to hide the hormones that create hunger and the food flavor begins to become more rewarding. At the same time, the body burns less calories while they are quiet.
After continuing people after the treatment of weight recovery pattern reflects people who considered people who plays in clinical trials and studies. 2022 Clinical Test Then for more than 200 people who took semaglutide for more than a year and lost 17% of body weight on average. When a subset of these participants stopped receiving the drug, about 12 percent of the body was restored within one year. They still had a net weight loss of 5%, a number that is clinically significant. 3 percent weight loss may be significant Benefit diabetes, hyperglycemia and dyslipidemia (What abnormal level of lipid places a higher risk of cardiovascular disease). These conditions, along with many others, often require higher weight loss to lead health improvements.
However, after leaving GLP-1 treatments, it is still ideal.
Other research paint a similar picture. 2021 in a short test, after 20 weeks semaglutide stopped people Recovered most of the lost weight in nearly one year But still, about 4 percent ended below the initial weight. And compared to 2022 research, the participants in this earlier study caused weight in a slower rhythm. 2021 Trial researchers followed the interventions of lifestyle, such as calories controlled diet and exercise, may help to slow down the rate. In another year of 2023, when people gave people to Tirzepatide, GLP-1 and similar metabolic hormone dependent on glucose is called insulinotropic glucose-dependent policyptic (GIP).Participants kept nearly 10% of their weight One year after stopping medication. In every example, however, there is no clear weight loss while staying in the long run.
“Considering, at least (at least), it could be returned to its basic weight,” says Nia Schwann Mitchell, a specialist in the University of Duke Professor and Weight management specialist.
Researchers also indicate the GLP-1 agonist recipients Treat more than obesity. Drugs were originally developed as types of type 2 diabetes and have been demonstrated, such as blood sugar, blood pressure and cholesterol levels. The Food and Drug Administration also accepts WEGOVY Treatment of heart diseaseand as an ocempic treatment Reduce the risks of chronic kidney diseases. And the evidence suggests that drugs stop the health of many of these health benefits.
In the trial of 2022 semagluturus, they returned to the levels of protected by the blood pressure reading of participants after stopping medication. Some biological markers, such as cholesterol and reactive protein (a measure of inflammation), is a little improved. For people who made a trial with prediabete, only 6% had this situation after taking drugs, but after a year, many of them returned to the premiary state.
Interestingly, the 2022 trials revealed the advantages that came out dependent on the magnitude of the loss of the initial weight. The more people lost, the less likely health improvement is maintained, even after you get a little weight. This reflects discoveries among the previous two types of diabetes after intensive lifestyles after losing weight: Those who lost more weight improved the level of Hemoglobina A1c (blood sugar size) after four yearsEven after recovering all the weight.
Without longer follow-up, however, it is difficult to determine whether any of these permanent changes will last. “This is not healing; it is a treatment,” Anecwe says. “You are removing treatment, and the disease will return. That’s what we see quite.”
Some clinics are looking for answers about changing doses when people can help people maintain their goals and weight goals. “Can we reduce the dose? Can you give the dose every week?” Mitchell says. “We don’t know.” Initial data presented in May 2024 at the European Congress of Obesity Throwing medications in nine weeks led to a steady body weight six months later. If these early results maintain replica trials, this may not require treatment indefinitely. But Anecwe says it is still too early to get the conclusion from the study, it has been small and yet to be reviewed.
“Anecdotically, we can see that the hunger bounce is stronger when you suddenly stop the tapering versus,” says Anekewek. “But I don’t think he was examined in a sharp way.”
Instead of developing an external dose of dose, other experts say that these drugs should be treated as medications in other chronic diseases. “No one will tell you when blood pressure is under control of medication,” says Sadiya Khan, a teacher of cardiovascular epidemiology and a preventive cardiologist. Jaiz The editorial made a case More research to understand why people came out.
Many factors help to be high in interruptions, but one is the main reason: the cost. “Insurance can play a really important role here,” says Tricia Rodriguezek, the author of the latest major authors Jama Network open Applied studies and applied scientists in Trubeta research, informing healthcare research research to report informed research, security control and help clinical trials. Those with type 2 diabetes have time harder to achieve insurance coverage for these medications, Rodriguez says. And brand, including Wegovy and Ozempic, Often cost about $ 1,000 per month out of pocket. In general, insurers do not cover the drug for pridencies.
Rodriguez and his colleagues had no insurance coverage in the new study looked directly, people with larger senarines had a greater chance of linking to medication. People who struggled with the gastrointestinal side effects also had to quit. But for many they stopped, it wasn’t necessarily a lasting decision; One-third of those with type 2 diabetes restarted the drug, often after regaining weight. Researchers do not investigate the effects of stopping and restarting drugs.
Why someone stopped and restart these medications is a hue of the question. It could be a mix of renewed access, changes in insurance coverage and medical factors. People Perceptions of weight and obesity It is also likely to have a strong role. “Sometimes (GLP-1 medications) are painted as aesthetic drugs, and obesity (presented) as a cosmetic problem,” Khan says. “I think stigma creates problems, both for both patients” clinicals. “
